

- Optimal relief from breakthrough pain is best attained by administering analgesics with dissolution times and bioavailabilities that closely match the onset and duration of breakthrough pain.
- Sublingual fentanyl tablets are approved for the treatment of breakthrough cancer pain in patients who are opioid tolerant.
- Time to complete disintegration of single 100, 200, or 300 µg sublingual fentanyl tablets was measured in 30 opioid-tolerant patients with chronic pain in an open-label, non-randomized, single-center US study.
- Sublingual fentanyl tablets dissolved rapidly (average time <2 min), with no significant differences by dose, sex, or age.

This summary slide represents the opinions of the authors, and not necessarily the opinions of the publisher or editorial board. This material has been peer reviewed. Craig Albright, PhD, and John Decker, PhD, of Complete Healthcare Communications, Inc., Chadds Ford, PA, USA, provided editorial support for the development of this manuscript with funding from ProStrakan Inc., Bridgewater, NJ, USA and Galena Biopharma, Portland, OR, USA. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online.